Review decision – May 2021
Decision that a part-review of the guidance should be planned into the appraisal work programme
The existing recommendations are optimised for a narrower population than covered by the marketing authorisations. Stakeholders have indicated that only recommending the use of these treatments to when a person has a forced vital capacity (FVC) between 50% and 80% predicted does not reflect current clinical practice, and that there may be new information to warrant an update of the guidance.
On consideration of the available evidence, NICE’s Guidance Executive has decided that a part-review of the guidance will be planned into the appraisal work programme to consider the patient population not currently recommended to receive treatment in the existing guidance.
This page was last updated: